Epidemiology of Hepatitis C Virus in the private blood banking sector in Osogbo, Southwest Nigeria

Muhibi  MA; Mabayoje VO; Abdul-Azeez A A; Adejumo BI

doi:10.52981/sjms.v9i3.1198

Muhibi MA Achievers University, Owo, Ondo State, Nigeria
Mabayoje VO College of Health Sciences, LadokeAkintola University of Technology, Ogbomoso, Oyo State, Nigeria
Abdul-Azeez A A Kwara State University, Malete- Ilorin - Nigeria.
Adejumo BI School of Basic Medical Science, College of Health Sciences, University of Benin, Benin City, Edo State, Nigeria

DOI: https://doi.org/10.52981/sjms.v9i3.1198

Keywords: Blood Safety, Hepatitis C Virus, Serology and Private sector.

Abstract

Background: Hepatitis C Virus (HCV) is an agent of Transfusion Transmissible Infection (TTI) which serves as a threat to blood safety and sufficiency of blood and blood products supply.
Objectives: This study aimed at determining the distribution patterns of HCV among potential blood donors in a private Blood Bank in Osogbo, Nigeria.
Materials and Methods: Over a period of 6 months, 290 consenting prospective blood donors were recruited for this study by convenient sampling technique. Pre-test counseling was done, before blood specimen collection and laboratory serological analysis was carried out, using third generation Enzyme Immunoassay Technique.
Results: The mean age of the respondents was 35.99 ±10.94 years. A total of 6 participants (2.07%) tested positive for anti-HCV. In this study, HCV prevalence has no association with age and blood type, but it does with the donor type, where the prevalence is higher among commercial blood donors.
Conclusion: The rates were lower than the previous studies in Nigeria perhaps this is due to the positive effect of public awareness on transfusion transmissible infections and the fact that majority of the donors were regular donors. Blood transfusion services should be further strengthened by establishment of blood transfusion committees at State level, to regulate and monitor the practice, especially in the private sector, with a view to ensure that stringent criteria are adhered to in blood donors’ selection.

Author Biographies

Muhibi MA, Achievers University, Owo, Ondo State, Nigeria

Haematology Unit, Medical Laboratory Science
Departmen

Haematology and Blood Transfusion Department

Mabayoje VO, College of Health Sciences, LadokeAkintola University of Technology, Ogbomoso, Oyo State, Nigeria

Haematology and Blood Transfusion Department

Abdul-Azeez A A, Kwara State University, Malete- Ilorin - Nigeria.

Department of Biosciences and Biotechnology

Adejumo BI, School of Basic Medical Science, College of Health Sciences, University of Benin, Benin City, Edo State, Nigeria

Medical Laboratory Science Department

References

1. European Convention on Human Rights and Biomedicine (1997, "Oviedo Convention"). Available at: http://conventions.coe.int/Treaty/en/Treaties/Html/ 164.htm. Accessed on 08/02/2013.
2. Nuffield Council on Bioethics. Human bodies: donation for medicine and research. 2011. Available at: www.nuffieldbioethics.org/sites/default/files/Dona tionfullreport.pdf. Accessed on 08/02/2013.
3. Italian Ministry of Health. Decree of 12 April, 2012 Modalities of the submission and evaluation of applications aimed at obtaining the insertion between the centers and manufacturing companies. Medicinal blood products authorized to enter into contractual agreements with the Regions and Autonomous Provinces for the processing of plasma collected throughout the country. Official Gazette of theItalian Republic - General Series June 26 , 2012; 147.
4. Liumbruno GM, Sodini ML, Grazzini G. TuscanStudy on the Appropriateness of fresh-frozen Plasma Transfusion (TuSAPlaT). Blood Transfus.2007; 5: 75-84.
5. World Health Organization. AIDE-MEMOIRE for National Health Programmes.The Clinical Use of Blood. Geneva, Switzerland: World Health Organization; 2003. Available at:http://www.who.int/bloodsafety/ clinical_use/en/Aide-Memoire_23.3.04.pdf. Last accessed on 26/04/2012.
6. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) 2001-2002. Public Data General Release File Documentation.2004; Pp1-16.
7. Rouet F, Marie-Laure C, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F and Rouzioux C. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study. Journal of Medical Virology; 2004;74: 34-40.
8. Terry Alli OA, OlusogaOgbolu D, Oluremi AS, Okanlawon BM,Uche LN and Muhibi MA. Seroprevalence of HTLV-I/II amongst Blood Donors in Osogbo, Nigeria.Sudan JMS 2011; 6 (3): 29-34.
9. Centers for Disease Control and Prevention.Summary of notifiable diseases- United States, 2000 Morbidity and Mortality Weekly Report (MMWR).2002; 49:10-11.
10. Egah DZ, Mandong BM, Iya D, Gomwalk NE, Audu ES, Banwat EB and Onile BA.Hepatitis C virus antibodies among blood donors in Jos, Nigeria.Annals of African Medicine.2004; 3 (1): 35 – 37.
11. .Mutimer DJ, Olomu, A.Skidmore, S.Olomu, N Ratcliffe, D Rodgers, B. Mutimer, H. P.Gunson, B.K. and Elias, E. Viral hepatitis in Nigeria-sicklecell disease andcommercial blood donors .Qt. J. Med.1994;87(7):407-411. 12. Wansbrough-Jones MH, Frimpong E, Cant B, Harris K, Evans MR and Teo CG.Prevalence and genotype of hepatitis C virus infection in pregnant women and blooddonors in Ghana. Transactions of Royal Society of Tropical Medicine and Hygiene.1998;92:496-499.
13. Koate BBD, Buseri FI, Jeremiah ZA. Seroprevalence of hepatitis C virus among blooddonors in Rivers State, Nigeria.Transfusion Medicine.2005;15:449-451.
14. Halim NK and Ajayi OI.Risk factors and seroprevalence of hepatitis C antibody inblood donors in Nigeria.East Afr. Med J. 2000;77(8):410-412.
15. Salawu L, Bolarinwa R A, Adegunloye A B, Muraina H A. HBsAg, anti-HCV, anti-HIV and VDRL in blood donors:Prevalence and trends in the last three and a half years in a tertiary health care facility in Ile-Ife, Nigeria, International Journal of Medicine and Medical Sciences.2010; 2(11), 335-341.
16. World Health Organization (WHO). Hepatitis CGlobal Surveillance Update. Weekly Epidemiological Records.2002; 75: 11-28.
17. Muhibi M A, Hassan A O, Muhibi M O. Assessment of ethical and other professional standards in private medical laboratories: Osun State experience.Journal of Medical Laboratory and Diagnosis.2012; 3(1), 7- 9.
18. DIA.PRO, Italy.HCV Ab third generation enzyme immunoassay for the determination of anti-HCV in human serum and plasma.2011; 1-8.
19. Isa AH, Hassan A, Mamman AI. Seroprevalence of hepatitis C virus antibodies among blood donors in Ahmadu Bello University Teaching Hospital, Kaduna.Afr. J. Cln. Exper.Microbiol.2009; 11: 75- 78.
20. .FiekumoIgbidaBuseri, Musa AbidemiMuhibi, ZaccheausAwortu Jeremiah. Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, south-west Nigeria. Blood Transfus.2009; 7(4): 293–299.
21. Stevens CE, Taylor PE and Pindyck J. Epidemiology of Hepatitis C virus. Journal of American Medical Association.1997; 263: 49-53.
22. Alter HJ, Conry-Catilena C, Melpolder J, Tan D, Van Raden, Herion D, Lau D and
23. Hoofnagle JH. Hepatitis C in Asymptomatic Blood Donors.Hepatology.1997; 26 (3):29S-33S.
24. Sharara AI, Hunt CM and Hamilton JD.Hepatitis C. Annals of Internal Medicine.1996; 125: 658 668.